Doravirine Suppresses Common Nonnucleoside Reverse Transcriptase Inhibitor-Associated Mutants at Clinically Relevant Concentrations

Antimicrobial Agents and Chemotherapy
Meizhen FengMing-Tain Lai

Abstract

Doravirine (DOR), which is currently in a phase 3 clinical trial, is a novel human immunodeficiency type 1 virus (HIV-1) nonnucleoside reverse transcriptase inhibitor (NNRTI). DOR exhibits potent antiviral activity against wild-type virus and K103N, Y181C, and K103N/Y181C mutant viruses, with 50% inhibitory concentrations (IC50s) of 12, 21, 31, and 33 nM, respectively, when measured in 100% normal human serum (NHS). To assess the potential for DOR to suppress NNRTI-associated and rilpivirine (RPV)-specific mutants at concentrations achieved in the clinic setting, inhibitory quotients (IQs) were calculated by determining the ratio of the clinical trough concentration over the antiviral IC50for each virus with DOR and RPV and efavirenz (EFV). DOR displayed IQs of 39, 27, and 25 against the K103N, Y181C, and K103N/Y181C mutants, respectively. In contrast, RPV exhibited IQs of 4.6, 1.4, and 0.8, and EFV showed IQs of 2.5, 60, and 1.9 against these viruses, respectively. DOR also displayed higher IQs than those of RPV and EFV against other prevalent NNRTI-associated mutants, with the exception of Y188L. Both DOR and EFV exhibited higher IQs than RPV when analyzed with RPV-associated mutants. Resistance selections were conducted with...Continue Reading

References

Aug 8, 1998·The New England Journal of Medicine·S H MichaelsP Kissinger
Dec 18, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Karin J MetznerMatthias Cavassini
Mar 18, 2009·Antimicrobial Agents and Chemotherapy·Ming-Tain LaiMichael D Miller
Apr 18, 2009·Current Opinion in HIV and AIDS·Charles la Porte
Sep 1, 2011·AIDS Research and Human Retroviruses·Toshibumi TaniguchiEdgar Turner Overton
Sep 12, 2012·Antimicrobial Agents and Chemotherapy·Edward P AcostaChristos J Petropoulos
Jan 1, 2014·Antimicrobial Agents and Chemotherapy·Ming-Tain LaiMichael D Miller

❮ Previous
Next ❯

Citations

Mar 21, 2018·Expert Opinion on Pharmacotherapy·Margaret R CaplanKatya C Corado
Mar 21, 2018·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·Rosa I SanchezSauzanne G Khalilieh
Oct 14, 2017·The Journal of Antimicrobial Chemotherapy·Ming-Tain LaiRoman A Melnyk
Jun 13, 2018·Antimicrobial Agents and Chemotherapy·Wendy AnkromSauzanne G Khalilieh
Aug 4, 2018·The Annals of Pharmacotherapy·Jamielynn C Sebaaly, Denise Kelley
Nov 23, 2016·Antimicrobial Agents and Chemotherapy·Ka Lai YeeSauzanne G Khalilieh
Oct 21, 2018·Drugs·Emma D Deeks
Nov 27, 2018·The Journal of Antimicrobial Chemotherapy·Cathia SoulieAnne-Geneviève Marcelin
Feb 13, 2019·Antimicrobial Agents and Chemotherapy·Kelly BleasbyRosa I Sanchez
Feb 13, 2019·Antimicrobial Agents and Chemotherapy·Ka Lai YeeLarissa Wenning
Feb 21, 2019·Antimicrobial Agents and Chemotherapy·Sauzanne G KhaliliehMarian Iwamoto
Feb 21, 2019·Antimicrobial Agents and Chemotherapy·Wendy AnkromSauzanne Khalilieh
Aug 17, 2019·The Annals of Pharmacotherapy·Sarah R BlevinsDavid B Cluck
Apr 10, 2020·Expert Opinion on Drug Metabolism & Toxicology·Megan NearyAdeniyi Olagunju
Jun 17, 2020·Expert Review of Clinical Pharmacology·Andrea GiacomelliStefano Rusconi
May 26, 2018·Current Opinion in HIV and AIDS·Marie-Alice Colombier, Jean-Michel Molina
Sep 27, 2019·Expert Opinion on Drug Metabolism & Toxicology·Yali WangGuangdi Li
Aug 8, 2019·Clinical Pharmacokinetics·Alison BoyleSaye Khoo
Sep 26, 2020·The Journal of Antimicrobial Chemotherapy·Francesco SaladiniMaurizio Zazzi
Apr 16, 2019·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Margaret JohnsonUNKNOWN DRIVE-SHIFT Study Group
Sep 15, 2020·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Elizabeth Anne MartinErnest Asante-Appiah
Jan 29, 2021·Chemical Reviews·Maria E CilentoStefan G Sarafianos
Apr 16, 2021·The Journal of Antimicrobial Chemotherapy·Bluma G BrennerRéjean Thomas
Jun 22, 2021·The Journal of Antimicrobial Chemotherapy·Minh Patrick LêLaurent Mandelbrot
Oct 18, 2019·ACS Infectious Diseases·Carey HwangDaria J Hazuda
Aug 17, 2021·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Arturo CicculloSimona Di Giambenedetto
Feb 21, 2019·ACS Medicinal Chemistry Letters·Nicole PributStephen C Pelly
Sep 28, 2021·Antimicrobial Agents and Chemotherapy·Ernest Asante-AppiahJay A Grobler

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.